SYAM KUNAM: Open Payments
NPI 1578525499 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,794 in 305 payments from 18 companies in 2025. Trend: 2023 $4,253 · 2024 $4,109 · 2025 $5,794
Food & beverage: $5,605Education: $189
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 60 | $1,174 |
| Otsuka America Pharmaceutical, Inc. | 46 | $766 |
| Teva Pharmaceuticals USA, Inc. | 38 | $729 |
| Alkermes, Inc. | 24 | $564 |
| Janssen Pharmaceuticals, Inc | 29 | $516 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $410 |
| E.R. Squibb & Sons, L.L.C. | 26 | $401 |
| Neurocrine BioSciences, Inc. | 19 | $388 |
| Lundbeck LLC | 17 | $202 |
| Vanda Pharmaceuticals Inc. | 12 | $158 |
Products named: VRAYLAR, REXULTI, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR, COBENFY, INGREZZA, ARISTADA.
Industry payments across CA — which companies pay providers there.
